Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCd induction/consolidation followed by pomalidomide vs pomalidomide + dexamethasone maintenance in relapsed or refractory multiple myeloma
NL-OMON24039Recruiting
- Sponsor
- HOVON
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pomalidomide, carfilzomib, dexamethasone and melphalan in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Progression-free survival from randomization and Response rate after induction and consolidation. Started Jul 2015; status: recruiting.
02
Drugs
pomalidomidecarfilzomibdexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON24039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24039.